Search This Blog

Friday, June 27, 2014

CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union (NYSE:LLY)

INDIANAPOLIS and RIDGEFIELD, Conn., June 27, 2014 /PRNewswire/ -- The Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval for the investigational compound LY2963016, a new insulin glargine product, for the treatment of type 1 and type 2 diabetes. The new insulin glargine product from Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim is the first biosimilar insulin recommended for approval in the European Union (EU).
Lilly/BI's insulin glargine is a basal insulin, which is intended to provide long-lasting blood sugar control between meals and at night, an integral part of glycemic control.1 It has the same amino acid sequence as Lantus® (insulin glargine) and was filed through the European Medicines Agency's (EMA) biosimilar pathway.


CHMP Recommends Lilly and Boehringer Ingelheim's Investigational New Insulin Glargine Product for Approval in the European Union (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.